Investigation of antidepressant efficacy of oral ketamine treatment

This double-blind, placebo-controlled trial (n=60) aimed to investigate the antidepressant efficacy of oral ketamine treatment in patients experiencing a major depressive episode within the scope of major depressive or bipolar disorder (MDD/BD).

Conducted by the Medical University of Vienna in Austria, the trial spanned a duration of approximately 2 years. The primary objective was to assess the antidepressant efficacy of oral ketamine in a randomized and controlled study design, with secondary objectives focusing on tolerability and clinical utility.

The trial involved adults aged 18 to 64, diagnosed with a major depressive episode. Notable exclusion criteria included recent initiation of antidepressant treatment and substance abuse history.

The trial utilized two treatment arms, involving the administration of oral ketamine and a comparator, midazolam hydrochloride. The primary endpoint was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) before and after treatment sessions. Secondary endpoints included the Clinician Administered Dissociative States Scale (CADSS) evaluation.

The trial concluded on October 13, 2021, with authorized Competent Authority Decision and favorable Ethics Committee Opinion received.

Topic Depression Bipolar Disorder
Compound Ketamine
Country Austria
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.